Group 1 - BioMarin Pharmaceutical (NASDAQ:BMRN) is identified as a promising large-cap stock under $100 with significant upside potential, with price targets revised upwards by analysts [1][3] - Canaccord Genuity analyst Whitney Ijem upgraded her rating from Hold to Buy and increased the price target from $84 to $98, indicating a potential upside of nearly 75% [1][2] - Truist Securities analyst Joon Lee also raised his price target from $80 to $100, suggesting a potential upside of approximately 78% while maintaining a Buy rating [3] Group 2 - Both analysts attribute their positive outlook to BioMarin's potential acquisition of Amicus Therapeutics, which is expected to be finalized in the second quarter of 2026 [4] - The acquisition is seen as strategically aligned with BioMarin's focus on rare diseases and its existing drug portfolio, particularly highlighting Amicus's approved drugs, Galafold and PomOp [4] - The deal is anticipated to be accretive within 12 months, further enhancing BioMarin's growth prospects [4] Group 3 - BioMarin specializes in developing and commercializing targeted therapies for life-threatening medical conditions and rare genetic diseases, with key products including VIMIZIM, VOXZOGO, NAGLAZYME, and ALDURAZYME [5] - The company operates in over 70 countries and has a robust pipeline of drugs in various stages of development [5]